Prof. Dr. Michael Sticherling

Professur für Dermatologie

Infektiöse Reisedermatosen (2020) Rongisch R, Schmidt E, Deresz N, Deresz K, Schöfer H, Schäkel K, Jakob T, et al. Journal article STRUCTURAL ENTHESEAL LESIONS IN PSORIASIS PATIENTS ARE ASSOCIATED WITH AN INCREASED RISK OF PROGRESSION TO PSORIATIC ARTHRITIS - A PROSPECTIVE COHORT STUDY (2020) Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Hueber A, Rech J, et al. Conference contribution TYPE 3 INNATE LYMPHOID CELLS ARE KEY DRIVERS OF PSORIATIC ARTHRITIS (2020) Raimondo MG, Rauber S, Luber M, Rigau AR, Weber S, Anchang CG, Agarwal R, et al. Conference contribution S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update (2020) Schmidt E, Sticherling M, Sárdy M, Eming R, Goebeler M, Hertl M, Hofmann SC, et al. Journal article S2k-Leitlinie zur Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids: 2019 Update (2020) Schmidt E, Sticherling M, Sárdy M, Eming R, Goebeler M, Hertl M, Hofmann SC, et al. Journal article Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany (2020) Heratizadeh A, Haufe E, Stoelzl D, Abraham S, Heinrich L, Kleinheinz A, Wollenberg A, et al. Journal article Itching and Neurodermatitis: Results from the German Neurodermatitis Register TREATgermany (2020) Haufe E, Heinrich L, Weisshaar E, Abraham S, Heratizadeh A, Harder I, Kleinheinz A, et al. Conference contribution Insights From the Apremilast After Switching From Fumaric Acid Ester Treatment (APART) Study: An Interim Real-World Safety Analysis (2020) Mrowietz U, Ertner K, Sticherling M, Grosse V, Popp G, Schwichtenberg U, Karl L, et al. Conference contribution Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS) (2020) Thaci D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, et al. Journal article Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study (2020) Reich K, Koerber A, Mrowietz U, Sticherling M, Sieder C, Frueh J, Bachhuber T Journal article